?? Costunolide (Saussurea Lactone) 98%

CAS: 553-21-9
Molecular Formula: C??H??O?
Molecular Weight: 232.32
Appearance: White crystalline powder

?? Core Value Proposition

Dual-Action Anti-Inflammatory & Cancer Chemopreventive Agent

• ≥98% Purity: Pharmaceutical grade (HPLC-verified, dual COA with NMR/MS)

• Multi-Target Bioactivity: Inhibits NF-κB/AP-1 pathways and induces ROS-mediated apoptosis

• Thermostable & Lipid-Soluble: Ideal for oral formulations and topical delivery systems

? Clinically Validated Benefits

1. Anti-Cancer Efficacy:

   • Suppresses NF-κB p65 subunit in ER? breast cancer (MDA-MB-231) at 20–40 μM, reducing tumor viability by 78% without toxicity to normal mammary cells (MCF-10A).

   • Induces mitochondrial permeability transition in HL-60 leukemia cells, triggering cytochrome c release and apoptosis.

2. Anti-Inflammatory & Antipyretic Effects:

   • Oral dose of 0.15 mg/kg abolishes LPS-induced fever and reduces carrageenan-induced paw edema by 62% in murine models.

   • Inhibits IL-1β expression by 75% in RAW 264.7 macrophages via blockade of JNK/p38 MAPK pathways.

3. Osteoprotective & Metabolic Regulation:

   • Dose-dependently inhibits RANKL-induced osteoclast differentiation by suppressing c-Fos/NFATc1 signaling, preventing bone resorption.

   • Exhibits hypoglycemic and hypolipidemic activity in diabetic models.

?? Technical Specifications

?? Pharmaceutical & Nutraceutical Applications

• Oncology Adjuvants:
  Synergizes with paclitaxel at 10–25 μM to enhance apoptosis in solid tumors.

• Anti-Arthritis Formulations:
  At 5 mg/kg/day oral dose, reduces joint inflammation and osteoclast activation in RA models.

• GI Disorder Therapeutics:
  Dual modulation of gastrointestinal motility—spasmolytic at low doses (0.1 mg/kg), prokinetic at higher doses (1 mg/kg).

• Metabolic Health Supplements:
  50–100 mg doses improve insulin sensitivity and reduce fasting glucose by 18%.

?? Competitive Advantages

• Green Extraction Technology:
  CO? supercritical fluid extraction yields 92% purity in initial phase, reducing solvent residues by 40% vs. ethanol methods.

• Enhanced Bioavailability:
  Liposome encapsulation increases oral absorption 3.8× (AUC: 29.7 μg·h/mL vs. 7.8 μg·h/mL free form).

• • 

     
  • 

     
  • 

     
  • 

     

?? Packaging & Delivery

? FAQ

• How to validate NF-κB inhibition?
  Free in vitro assay report (p65/p52 subunit Western blot) included with every batch.

• Compatibility with hydrophilic carriers?
  Use β-cyclodextrin complexation for water-soluble injectables (solubility ↑8× to 16 mg/mL).

• Stability in topical creams?
  Maintains >95% potency for 18 months in anhydrous bases (pH 5.0–7.0); avoid UV exposure.

?? Why Partner With Us?

• Ethical Sourcing:
  Aucklandia lappa cultivated via regenerative agroforestry in Xinjiang (zero pesticides, blockchain traceability) 410.

• Custom Derivatives:
  Costunolide Palmitate: Oil-soluble for transdermal patches
  Glycosylated Costunolide: Enhanced bioavailability for nutraceuticals